Trinity Biotech plc announced the appointment of Jerry Lydon as Head of North America Commercial Operations. Mr. Lydons appointment represents a deliberate next step as the Companys core diagnostics business transitions from the execution phase of its Comprehensive Transformation Plan toward a sustained focus on building revenue momentum and, importantly, driving profitability from a more efficient and disciplined operating base. The appointment also aligns with recent upgrades to the Companys Premier HbA1c 9210 platform, the Companys laboratory blood glucose monitoring solution.
The enhanced Premier Hb9210 platform recently became the only HbA1c system worldwide to receive the prestigious International Federation of Clinical Chemistry Gold classification for 2026, a designation recognising the highest levels of clinical accuracy, precision and traceability. Over the past two years, Trinity has implemented a wideranging transformation program designed to simplify its operating footprint, improve cost control, rationalise manufacturing, and prioritise profitability. With many of these foundational actions substantially completed, management is now focused on extracting greater operating leverage and financial returns from that improved structure, including across the North America business.
Jerry Lydon brings extensive commercial leadership experience in diagnostics and healthcare, with a strong track record of improving sales execution, managing distributor and direct sales channels. In his role, Mr. Lydon will oversee Trinitys North America commercial organisation, with responsibility for commercial execution across the core diagnostics portfolio. As part of this role, Mr. Lydon will lead commercial operations for the Companys New York State Department of Healthapproved reference laboratory, including supporting the commercialisation planning for a pipeline of new products in development, such as: //st EpiCapture, a proprietary epigenetic assay for prostate cancer monitoring, and PrePsia, a proprietary early-pregnancy blood test to assess risk of developing preeclampsia, a serious pregnancy complication.
